Suppr超能文献

CD70 是一种潜在的预后标志物,可显著调节弥漫性大 B 细胞淋巴瘤中的细胞功能。

CD70 is a potential prognostic marker and significantly regulates cellular function in diffuse large B-cell lymphoma.

机构信息

Hematology Laboratory, Central Hospital of Xiangtan, Xiangtan, China.

Department of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd., Wuhan, China.

出版信息

PLoS One. 2024 Oct 24;19(10):e0312445. doi: 10.1371/journal.pone.0312445. eCollection 2024.

Abstract

Extensive research has demonstrated that dysregulation of costimulatory molecule expression plays a pivotal role in cancer biology. However, the impact of intratumoral CD70 on the initiation, progression, and immune response in diffuse large B-cell lymphoma (DLBCL) remains poorly understood. This study aims to elucidate the clinical significance of CD70 in DLBCL diagnosis and prognosis, as well as its relationship with the immune microenvironment. We first analyzed CD70 expression across various cancers, including DLBCL, using multiple online databases (TIMER, GEPIA, GENT2, TNMPlot, GSCA, and GEO). We then evaluated the clinical correlations and prognostic value of CD70 in DLBCL. Additionally, we investigated the functional role of CD70 in DLBCL cells. Genomic alterations of CD70 were analyzed using the cBioPortal online tool. Co-expression network analysis was performed to assess the biological functions associated with CD70. Furthermore, we utilized TIMER2.0 to examine the correlation between CD70 expression and immune cell infiltration. Our results revealed that CD70 expression was significantly upregulated in DLBCL tissues compared to matched normal tissues, and high CD70 expression was associated with poor clinical outcomes in DLBCL patients. In vitro experiments demonstrated that CD70 inhibition promotes apoptosis and induces G1 phase arrest in DLBCL cells. Genomic alteration analysis showed that patients with CD70 alterations exhibited worse overall survival compared to those without such alterations. Co-expression and functional enrichment analyses indicated that CD70 is functionally related to tumor necrosis factor receptor binding and the NF-κB signaling pathway. Moreover, we found that CD70 expression levels were negatively correlated with B cell and NK cell infiltration in DLBCL. In conclusion, this study suggests that CD70 is a potential diagnostic and therapeutic biomarker for DLBCL. Our findings provide valuable insights for the development of novel therapeutic strategies targeting CD70 in DLBCL treatment.

摘要

大量研究表明,共刺激分子表达失调在癌症生物学中起着关键作用。然而,肿瘤内 CD70 对弥漫性大 B 细胞淋巴瘤 (DLBCL) 的起始、进展和免疫反应的影响仍知之甚少。本研究旨在阐明 CD70 在 DLBCL 诊断和预后中的临床意义,以及其与免疫微环境的关系。我们首先使用多个在线数据库 (TIMER、GEPIA、GENT2、TNMPlot、GSCA 和 GEO) 分析了 CD70 在各种癌症中的表达,包括 DLBCL。然后,我们评估了 CD70 在 DLBCL 中的临床相关性和预后价值。此外,我们还研究了 CD70 在 DLBCL 细胞中的功能作用。使用 cBioPortal 在线工具分析 CD70 的基因组改变。进行共表达网络分析以评估与 CD70 相关的生物学功能。此外,我们利用 TIMER2.0 检查 CD70 表达与免疫细胞浸润之间的相关性。我们的研究结果表明,与匹配的正常组织相比,CD70 在 DLBCL 组织中的表达显著上调,并且高 CD70 表达与 DLBCL 患者的不良临床结局相关。体外实验表明,CD70 抑制可促进 DLBCL 细胞凋亡并诱导 G1 期阻滞。基因组改变分析表明,与未发生 CD70 改变的患者相比,发生 CD70 改变的患者总生存更差。共表达和功能富集分析表明,CD70 在功能上与肿瘤坏死因子受体结合和 NF-κB 信号通路相关。此外,我们发现 CD70 表达水平与 DLBCL 中的 B 细胞和 NK 细胞浸润呈负相关。总之,本研究表明 CD70 是 DLBCL 的潜在诊断和治疗生物标志物。我们的研究结果为开发针对 DLBCL 治疗中 CD70 的新型治疗策略提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb4c/11500843/2cd6c9197358/pone.0312445.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验